Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy: What's the problem with generic antiepileptic drugs? A call to action [1]

Neurology

Volumn 69, Issue 18, 2007, Pages 1806-

  Miller, John W ^a   Anderson, Gail D ^a   Doherty, Michael J ^a   Poolos, Nicholas P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; GENERIC DRUG; LAMOTRIGINE; TOPIRAMATE; ZONISAMIDE;

DRUG INDICATION; DRUG INDUSTRY; DRUG RESEARCH; EPILEPSY; HUMAN; LETTER; MEDICAL SOCIETY; PRESCRIPTION; PRIORITY JOURNAL;

EID: 35848930351     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000285526.77634.7d     Document Type: Letter

References (5)

1. K Liow GL Barkley JR Pollard CL Harden CW Bazil Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy Neurology 68 2007 1249 1250
2. MJ Berg What's the problem with generic antiepileptic drugs? A call to action Neurology 68 2007 1245 1246
3. CY Wu LZ Benet Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm Res 22 2005 11 23
4. Link to legislation available at: http://apps.leg.wa.gov/billinfo/summary.aspx?bill=2123
5. Harris G. FDA limits role of advisers tied to industry. The New York Times March 22, 2007.